These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
469 related articles for article (PubMed ID: 32877911)
1. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma. Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S Oncology; 2020; 98(11):779-786. PubMed ID: 32877911 [TBL] [Abstract][Full Text] [Related]
2. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma. Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907 [TBL] [Abstract][Full Text] [Related]
3. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib. Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H Oncology; 2019; 97(2):75-81. PubMed ID: 31242488 [TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266 [TBL] [Abstract][Full Text] [Related]
5. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115 [TBL] [Abstract][Full Text] [Related]
6. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967 [TBL] [Abstract][Full Text] [Related]
7. Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. Takahashi A; Moriguchi M; Seko Y; Ishikawa H; Yo T; Kimura H; Fujii H; Shima T; Mitsumoto Y; Ishiba H; Takashima H; Nagao Y; Jo M; Arai M; Hara T; Okajima A; Muramatsu A; Morita A; Yoshinami N; Nakajima T; Mitsuyoshi H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y Anticancer Res; 2019 Sep; 39(9):5149-5156. PubMed ID: 31519627 [TBL] [Abstract][Full Text] [Related]
8. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma. Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054 [TBL] [Abstract][Full Text] [Related]
9. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment. Yamashige D; Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Kajiwara A; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H Oncology; 2021; 99(3):169-176. PubMed ID: 33207358 [TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting. Obi S; Sato T; Sato S; Kanda M; Tokudome Y; Kojima Y; Suzuki Y; Hosoda K; Kawai T; Kondo Y; Isomura Y; Ohyama H; Nakagomi K; Ashizawa H; Miura Y; Amano H; Mochizuki H; Omata M Hepatol Int; 2019 Mar; 13(2):199-204. PubMed ID: 30671808 [TBL] [Abstract][Full Text] [Related]
11. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization. Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA Oncology; 2016; 91(6):317-330. PubMed ID: 27784014 [TBL] [Abstract][Full Text] [Related]
12. Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. Komatsu S; Yano Y; Mimura T; Minami A; Momose K; Hirano H; Tanaka M; Ueda Y; Tai K; Yasuhara Y; Nakagawa D; Yamamoto A; Kido M; Ueda Y; Kodama Y; Fukumoto T Anticancer Res; 2024 Jul; 44(7):3097-3103. PubMed ID: 38925835 [TBL] [Abstract][Full Text] [Related]
13. Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma. Baxter MA; Glen H; Evans TR Future Oncol; 2018 Aug; 14(20):2021-2029. PubMed ID: 29783903 [TBL] [Abstract][Full Text] [Related]
14. Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound. Kamachi N; Nakano M; Okamura S; Niizeki T; Iwamoto H; Shimose S; Shirono T; Noda Y; Kuromatsu R; Koga H; Torimura T Cancer Rep (Hoboken); 2022 Feb; 5(2):e1471. PubMed ID: 34105904 [TBL] [Abstract][Full Text] [Related]
15. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib. Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978 [TBL] [Abstract][Full Text] [Related]
16. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma. Hata K; Suetsugu K; Egashira N; Makihara Y; Itoh S; Yoshizumi T; Tanaka M; Kohjima M; Watanabe H; Masuda S; Ieiri I Cancer Chemother Pharmacol; 2020 Dec; 86(6):803-813. PubMed ID: 33095285 [TBL] [Abstract][Full Text] [Related]
17. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527 [TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339 [TBL] [Abstract][Full Text] [Related]
19. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1. Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654 [TBL] [Abstract][Full Text] [Related]
20. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib. Ikeda M; Kobayashi M; Tahara M; Kaneko S Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]